Financial Ratios Poolbeg Pharma PLC

Equities

POLB

GB00BKPG7Z60

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 09:05:02 15/05/2026 pm IST			5-day change	1st Jan Change
4.750 ^GBX	-3.06%		+9.20%	+18.75%

11/05	Central Asia Metals cancels share premium account	AN
11/05	Poolbeg Pharma Receives Patent Grant For POLB 001 Cancer Immunotherapy-Induced CRS In Canada	CI

9c916b25a5d7a86ea50d6.NCnAR8VBqM7LguI_5N9Y-1zqdHbM6PLS2OC-OWBnBJA.bGSZfpMUmZiU6opK0rdgrR-HQxG136SWqLfaUw0QT6d5bPkdqATbq4XkhQ

Published financial data: POOLBEG PHARMA PLC

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021	2022	2023	2024
Selling General & Admin Expenses, Total	27.08L	30.6L	33.76L	52.58L
R&D Expenses	6L	22.04L	16.77L	13.83L
Other Operating Expenses	-	-3L	-4L	-5L
Other Operating Expenses, Total	32.6L	49.86L	46.86L	61.11L
Operating Income	-32.6L	-49.86L	-46.86L	-61.11L
Interest And Investment Income	-	2L	5L	4L
Net Interest Expenses	-	2L	5L	4L
EBT, Excl. Unusual Items	-32.6L	-47.77L	-41.52L	-56.83L
Gain (Loss) On Sale Of Assets	-	-	-	-3L
Asset Writedown	-	-	-4L	-
Other Unusual Items	1L	-	-	-
EBT, Incl. Unusual Items	-31.15L	-47.77L	-45.05L	-59.44L
Income Tax Expense	-	-91T	-6L	-2L
Earnings From Continuing Operations	-31.15L	-46.86L	-39.31L	-57.9L
Net Income to Company	-31.15L	-46.86L	-39.31L	-57.9L
Net Income - (IS)	-31.15L	-46.86L	-39.31L	-57.9L
Net Income to Common Incl Extra Items	-31.15L	-46.86L	-39.31L	-57.9L
Net Income to Common Excl. Extra Items	-31.15L	-46.86L	-39.31L	-57.9L
Per Share Items
Net EPS - Basic	-0.01	-0.01	-0.01	-0.01
Basic EPS - Continuing Operations	-0.01	-0.01	-0.01	-0.01
Basic Weighted Average Shares Outstanding	32Cr	50Cr	50Cr	50Cr
Net EPS - Diluted	-0.01	-0.01	-0.01	-0.01
Diluted EPS - Continuing Operations	-0.01	-0.01	-0.01	-0.01
Diluted Weighted Average Shares Outstanding	32Cr	50Cr	50Cr	50Cr
Normalized Basic EPS	-0.01	-0.01	-0.01	-0.01
Normalized Diluted EPS	-0.01	-0.01	-0.01	-0.01
Supplemental Items
EBITDA	-32.36L	-49.6L	-46.6L	-59.97L
EBITA	-32.36L	-49.6L	-46.6L	-59.97L
EBIT	-32.6L	-49.86L	-46.86L	-61.11L
Effective Tax Rate - (Ratio)	-	1.9	12.74	2.59
Total Current Taxes	-	-91T	-6L	-2L
Normalized Net Income	-20.37L	-29.86L	-25.95L	-35.52L
Supplemental Operating Expense Items
General and Administrative Expenses	27.08L	30.6L	33.76L	52.58L
Research And Development Expense From Footnotes	6L	22.04L	16.77L	13.83L
Stock-Based Comp., Other (Total)	3L	4L	50T	6L
Total Stock-Based Compensation	3L	4L	50T	6L

Fiscal Period: December	2021	2022	2023	2024
Assets
Cash And Equivalents	2.09Cr	1.62Cr	1.22Cr	78.24L
Total Cash And Short Term Investments	2.09Cr	1.62Cr	1.22Cr	78.24L
Accounts Receivable, Total	8T	-	-	20T
Other Receivables	49T	84T	7L	3L
Total Receivables	57T	84T	7L	3L
Prepaid Expenses	4L	9L	7L	5L
Total Current Assets	2.15Cr	1.72Cr	1.35Cr	85.63L
Other Intangibles, Total	15.63L	21.34L	19.3L	16.84L
Total Assets	2.3Cr	1.93Cr	1.54Cr	1.02Cr
Liabilities
Accounts Payable, Total	79T	3L	79T	2L
Accrued Expenses, Total	4L	7L	9L	8L
Other Current Liabilities	3T	4T	9T	18T
Total Current Liabilities	4L	10L	10L	10L
Total Liabilities	4L	10L	10L	10L
Common Stock, Total	1L	1L	1L	1L
Additional Paid In Capital	2.31Cr	2.31Cr	2.31Cr	2.31Cr
Retained Earnings	-23.36L	-70.22L	-1.1Cr	-1.67Cr
Comprehensive Income and Other	17.16L	21.45L	21.95L	28.16L
Total Common Equity	2.26Cr	1.83Cr	1.44Cr	92.73L
Total Equity	2.26Cr	1.83Cr	1.44Cr	92.73L
Total Liabilities And Equity	2.3Cr	1.93Cr	1.54Cr	1.02Cr
Supplemental Items
ECS Total Shares Outstanding on Filing Date	50Cr	50Cr	50Cr	50Cr
ECS Total Common Shares Outstanding	50Cr	50Cr	50Cr	50Cr
Book Value / Share	0.05	0.04	0.03	0.02
Tangible Book Value	2.1Cr	1.62Cr	1.25Cr	75.89L
Tangible Book Value Per Share	0.04	0.03	0.03	0.02
Total Debt	0	0	0	0
Net Debt	-2.09Cr	-1.62Cr	-1.22Cr	-78.24L
Account Code - Inventory Valuation	3	3	3	3
Full Time Employees	7	12	15	16

Fiscal Period: December	2021	2022	2023	2024
Net Income	-31.15L	-46.86L	-39.31L	-57.9L
Amortization of Goodwill and Intangible Assets - (CF)	24T	26T	26T	1L
Depreciation & Amortization, Total	24T	26T	26T	1L
(Gain) Loss From Sale Of Asset	-	-	-	3L
Asset Writedown & Restructuring Costs	-	-	4L	-
Stock-Based Compensation (CF)	3L	4L	50T	6L
Other Operating Activities, Total	-	-2L	-11.08L	13T
Change In Accounts Receivable	-7L	-5L	2L	1L
Change In Accounts Payable	6L	5L	20T	-12T
Cash from Operations	-28.61L	-43.68L	-43.81L	-46.46L
Sale (Purchase) of Intangible assets	-1L	-6L	-2L	-1L
Other Investing Activities, Total	-	2L	5L	4L
Cash from Investing	-1L	-4L	4L	3L
Short Term Debt Issued, Total	2L	-	-	-
Total Debt Issued	3L	-	-	-
Short Term Debt Repaid, Total	-2L	-	-	-
Total Debt Repaid	-3L	-	-	-
Issuance of Common Stock	3.09Cr	-	-	-
Cash from Financing	3.09Cr	-	-	-
Net Change in Cash	2.79Cr	-47.56L	-40.22L	-43.47L
Supplemental Items
Levered Free Cash Flow	-	-31.86L	-33.73L	-26.37L
Unlevered Free Cash Flow	-	-31.86L	-33.73L	-26.37L
Change In Net Working Capital	-	-72T	3L	-6L
Net Debt Issued / Repaid	0	-	-	-

Fiscal Period: December	2021	2022	2023	2024
Profitability
Return on Assets	-	-14.73	-16.87	-29.75
Return on Total Capital	-	-15.24	-17.88	-32.21
Return On Equity %	-	-22.91	-24	-48.83
Return on Common Equity	-	-22.91	-24	-48.83
Short Term Liquidity
Current Ratio	48.98	17.76	13.69	8.79
Quick Ratio	47.96	16.85	13.01	8.31
Operating Cash Flow to Current Liabilities	-6.53	-4.52	-4.44	-4.77
Long Term Solvency
Total Liabilities / Total Assets	1.9	5.01	6.39	9.51
Net Debt / EBITDA	6.47	3.26	2.61	1.3
Net Debt / (EBITDA - Capex)	6.47	3.26	2.61	1.3
Growth Over Prior Year
EBITDA, 1 Yr. Growth %	-	60.48	-6.05	28.69
EBITA, 1 Yr. Growth %	-	60.48	-6.05	28.69
EBIT, 1 Yr. Growth %	-	60.08	-6.02	30.41
Earnings From Cont. Operations, 1 Yr. Growth %	-	50.45	-16.11	47.29
Net Income, 1 Yr. Growth %	-	50.45	-16.11	47.29
Normalized Net Income, 1 Yr. Growth %	-	53.37	-13.08	36.87
Diluted EPS Before Extra, 1 Yr. Growth %	-	-4.72	-15.96	46.84
Total Assets, 1 Yr. Growth %	-	-16.2	-20.02	-33.58
Tangible Book Value, 1 Yr. Growth %	-	-22.97	-22.71	-39.35
Common Equity, 1 Yr. Growth %	-	-18.85	-21.18	-35.79
Cash From Operations, 1 Yr. Growth %	-	52.66	0.3	6.05
Levered Free Cash Flow, 1 Yr. Growth %	-	-	5.85	-21.8
Unlevered Free Cash Flow, 1 Yr. Growth %	-	-	5.85	-21.8
Compound Annual Growth Rate Over Two Years
EBITDA, 2 Yr. CAGR %	-	-	22.79	9.96
EBITA, 2 Yr. CAGR %	-	-	22.79	9.96
EBIT, 2 Yr. CAGR %	-	-	22.66	10.71
Earnings From Cont. Operations, 2 Yr. CAGR %	-	-	12.34	11.16
Net Income, 2 Yr. CAGR %	-	-	12.34	11.16
Normalized Net Income, 2 Yr. CAGR %	-	-	15.46	9.07
Diluted EPS Before Extra, 2 Yr. CAGR %	-	-	-10.52	11.09
Total Assets, 2 Yr. CAGR %	-	-	-18.13	-27.11
Tangible Book Value, 2 Yr. CAGR %	-	-	-22.84	-31.53
Common Equity, 2 Yr. CAGR %	-	-	-20.03	-28.86
Cash From Operations, 2 Yr. CAGR %	-	-	23.74	3.13
Levered Free Cash Flow, 2 Yr. CAGR %	-	-	-	-9.02
Unlevered Free Cash Flow, 2 Yr. CAGR %	-	-	-	-9.02
Compound Annual Growth Rate Over Three Years
EBITDA, 3 Yr. CAGR %	-	-	-	24.73
EBITA, 3 Yr. CAGR %	-	-	-	24.73
EBIT, 3 Yr. CAGR %	-	-	-	25.19
Earnings From Cont. Operations, 3 Yr. CAGR %	-	-	-	22.96
Net Income, 3 Yr. CAGR %	-	-	-	22.96
Normalized Net Income, 3 Yr. CAGR %	-	-	-	22.2
Diluted EPS Before Extra, 3 Yr. CAGR %	-	-	-	5.55
Accounts Receivable, 3 Yr. CAGR %	-	-	-	35.72
Total Assets, 3 Yr. CAGR %	-	-	-	-23.64
Tangible Book Value, 3 Yr. CAGR %	-	-	-	-28.79
Common Equity, 3 Yr. CAGR %	-	-	-	-25.67
Cash From Operations, 3 Yr. CAGR %	-	-	-	17.54